Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Rating) – Research analysts at William Blair issued their FY2024 EPS estimates for Kinnate Biopharma in a report released on Thursday, March 16th. William Blair analyst T. Lugo expects that the company will post earnings per share of ($3.66) for the year. The consensus estimate for Kinnate Biopharma’s current full-year earnings is ($3.09) per share.
A number of other analysts have also recently weighed in on the stock. Wedbush cut their price objective on shares of Kinnate Biopharma from $29.00 to $25.00 and set an “outperform” rating on the stock in a report on Thursday. Stifel Nicolaus cut their price objective on shares of Kinnate Biopharma from $11.00 to $8.00 and set a “hold” rating on the stock in a report on Thursday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.
Kinnate Biopharma Trading Down 0.7 %
Kinnate Biopharma (NASDAQ:KNTE – Get Rating) last issued its earnings results on Wednesday, March 15th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.02).
Hedge Funds Weigh In On Kinnate Biopharma
A number of institutional investors have recently modified their holdings of the business. Alliancebernstein L.P. acquired a new position in shares of Kinnate Biopharma in the 4th quarter valued at $81,000. Jane Street Group LLC acquired a new position in shares of Kinnate Biopharma in the 4th quarter valued at $77,000. SVB Financial Group acquired a new position in shares of Kinnate Biopharma in the 4th quarter valued at $143,000. Squarepoint Ops LLC acquired a new position in shares of Kinnate Biopharma in the 4th quarter valued at $153,000. Finally, Marshall Wace LLP increased its holdings in shares of Kinnate Biopharma by 30.5% in the 4th quarter. Marshall Wace LLP now owns 14,944 shares of the company’s stock valued at $91,000 after acquiring an additional 3,492 shares during the period. 98.68% of the stock is owned by institutional investors and hedge funds.
About Kinnate Biopharma
Kinnate Biopharma Inc, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
- Get a free copy of the StockNews.com research report on Kinnate Biopharma (KNTE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.